Condition
SARS CoV 2 Vaccination
Total Trials
2
Recruiting
1
Active
1
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
1 treatments under study, led by Sarscov2 Vaccination
Research Leaders
5 sponsors active, led by Boston University
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
Trial Status
Recruiting1
Completed1
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (2)
Research Network
Common Treatments
- Sarscov2 Vaccination1
Active Sponsors
- Boston University1
- Burnet Institute1
- Kamuzu University of Health Sciences1
- National Institute of Allergy and Infectious Diseases (NIAID)1
- Sinai University1
Top Investigators
BU School of Public Health, Department of Global Health
BU School of Public Health, Department of Global Health
Kamuzu University of Health Sciences, Malaria Alert Center, Malawi
Burnet Institute, Australia
Related Conditions
- Sars Cov 2 Infection1